| [1] |
金众鑫，乔玉峰. 利妥昔单抗在难治性肾病综合征中的应用现状[J/CD]. 中华肾病研究电子杂志，2018, 7(5): 234-237.
|
| [2] |
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis [J]. N Engl J Med, 2014, 371(19): 1771-1780.
|
| [3] |
Gopaluni S, Smith R, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial [J]. Trials, 2017, 18(1): 112.
|
| [4] |
Rovin B, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study [J]. Arthritis Rheum, 2012, 64(4): 1215-1226.
|
| [5] |
Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis [J]. Eur J Rheumatol, 2018, 5(2): 118-126.
|
| [6] |
Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 2012, 23(8): 1416-1425.
|
| [7] |
Fervenza F, Appel G, Barbour S, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy [J]. N Engl J Med, 2019, 381(1): 36-46.
|
| [8] |
Wang X, Cui Z, Zhang Y, et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort [J]. Nephrol Dial Transplant, 2018, 33(9): 1558-1563.
|
| [9] |
Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome [J]. J Am Soc Nephrol, 2014, 25(4): 850-863.
|
| [10] |
Lafayette R, Canetta P, Rovin B, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction [J]. J Am Soc Nephrol, 2017, 28(4): 1306-1313.
|
| [11] |
Hamilton P, Kanigicherla D, Venning M, et al. Rituximab versus the modified ponticelli regimen in the treatment of primary membranous nephropathy : a health economic model [J]. Nephrol Dial Transplant, 2018, 33(12): 2145-2155.
|
| [12] |
付平，苟慎菊. 利妥昔单抗在肾脏疾病中的应用[J]. 肾脏病与透析肾移植杂志，2017, 26(1): 50-51.
|
| [13] |
Dooley M, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE [J]. Lupus, 2013, 22(1): 63-72.
|
| [14] |
Fakhouri F, Hourmant M, Campistol J, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial [J]. Am J Kidney Dis, 2016, 68(1): 84-93.
|
| [15] |
Bomback A, Smith R, Barile G, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis [J]. Clin J Am Soc Nephrol, 2012, 7(5): 748-756.
|
| [16] |
Greenbaum L, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome [J]. Kidney Int, 2016, 89(3): 701-711.
|
| [17] |
Licht C, Greenbaum L, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies [J]. Kidney Int, 2015, 87(5): 1061-1073.
|
| [18] |
Ruggenenti P, Daina E, Gennarini A, et al. C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial [J]. Am J Kidney Dis, 2019, 74(2): 224-238.
|
| [19] |
Ring T, Pedersen B, Salkus G, et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? [J]. Clin Kidney J, 2015, 8(5): 489-491.
|
| [20] |
Zhang Y, Yan X, Zhao T, et al. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice [J]. Clin Exp Immunol, 2017, 189(1): 60-70.
|
| [21] |
Dimopoulos M, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment [J]. J Clin Oncol, 2016, 34(13): 1544-1557.
|
| [22] |
Dimopoulos M, Roussou M, Gavriatopoulou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis [J]. Am J Hematol, 2016, 91(5): 499-502.
|
| [23] |
Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study [J]. Haematologica, 2015, 100(5): e207-e210.
|
| [24] |
Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial [J]. Haematologica, 2015, 100(7): 964-969.
|
| [25] |
Zhang H, Liu Z, Huang L, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis [J]. Lupus, 2017, 26(9): 952-958.
|
| [26] |
Yu C, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease [J]. N Engl J Med, 2013, 369(25): 2416-2423.
|
| [27] |
Delville M, Baye E, Durrbach A, et al. B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS [J]. J Am Soc Nephrol, 2016, 27(8): 2520-2527.
|
| [28] |
Shah Y, Almeshari K, Aleid H, et al. Successful treatment with abatacept in recurrent focal segmental glomerulosclerosis after kidney transplant [J]. Exp Clin Transplant, 2019, 17(Suppl 1): 178-180.
|
| [29] |
Jayne D, Bruchfeld A, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis [J]. J Am Soc Nephrol, 2017, 28(9): 2756-2767.
|
| [30] |
Merkel P, Jayne D, Wang C, et al. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: protocol for a randomized, double-blind, active-controlled, phase 3 trial [J]. JMIR Res Protoc, 2020, 9(4): e16664.
|
| [31] |
Grgic I, Chandraker A. Significance of biologics in renal transplantation: past, present, and future [J]. Curr Opin Organ Transplant, 2018, 23(1): 51-62.
|